Drugs News and Research

RSS

Mylan releases generic version of Invega in the U.S.

Mylan N.V. today announced the U.S. launch of Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg and 9 mg, the generic version of Janssen's Invega.

28 Sep 2015

Increasing availability of genetic tests for at-risk cancer patients

Mutations in the BRCA 1 and BRCA 2 genes are very likely to lead to a form of cancer in people who have them. These mutations can be detected using a genetic test. The introduction of a new drug has improved treatment options and this, coupled with increased awareness and improved access, increased the number of genetic tests carried out at the MedUni Vienna last year by a factor of five.

28 Sep 2015

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors. KTN0158 is a proprietary, humanized anti-KIT IgG1 monoclonal antibody drug candidate being developed as a potential therapy for cancer and mast cell-related diseases.

28 Sep 2015

Two-drug combination improves progression-free survival in patients with advanced melanoma

Patients with advanced melanoma skin cancer survive for longer without their disease progressing if they have been treated with a combination of two drugs, nivolumab and ipilimumab, than with either of these drugs alone. New results show that these patients also do better regardless of their age, stage of disease and whether or not they have a cancer-driving mutation in the BRAF gene.

28 Sep 2015

Combination of two targeted therapies increases survival in advanced melanoma

Latest results from a trial of a combination of two targeted therapies (dabrafenib and trametinib) to treat advanced melanoma have shown that patients are living significantly longer on the combined therapy than patients treated with another drug, vemurafenib, when used alone.

28 Sep 2015

Genetic mutations predict breast cancer relapse

A large genetics study has identified genetic mutations specific to recurrent breast cancer cells. Screening for these mutations in breast cancer tumours could therefore allow doctors to identify patients most at risk of their cancer returning. The relevant genes can then be targeted to prevent recurrence of the cancer.

27 Sep 2015

Investment in radiotherapy services could save lives, boost economy in developing countries

Millions of people are dying from potentially treatable cancers like breast and prostate because of a chronic underinvestment in radiotherapy resources, according to a major new Commission on access to radiotherapy, published in The Lancet Oncology, and being presented at the 2015 European Cancer Congress in Vienna, Austria.

26 Sep 2015

New technology benefits child suffering from severe form of epilepsy

Brittany Brown has watched her daughter, Amaree, 6, struggle with hundreds of seizures every day for the past six years. Yes, hundreds. Every day.

26 Sep 2015

New countries join ESMO Designated Centre of Integrated Oncology and Palliative Care

Patient eligibility for opioids is seriously restricted in some countries, with the highest rate of limited access to palliative care found in the Middle East, followed by Latin America and the Caribbean and Asia. Data are revealed by the ESMO Global Opioid Policy Initiative (GOPI) which identifies barriers to the availability and accessibility of essential pain relieving medication worldwide.

26 Sep 2015

New report sets out plans to improve cure rate, quality of life for childhood cancer survivors in Europe

Each year in Europe, 6,000 young people die from cancer, and two-thirds of those who survive suffer from treatment-related side effects. Although there has been considerable progress in the treatment of childhood cancers over the past few decades, and cancer in childhood is rare, these are major problems that need to be overcome, says a report from SIOPE, the European Society for Paediatric Oncology, launched at the 2015 European Cancer Congress today.

26 Sep 2015

Creating a new paradigm for management of yeast infections

Yeasts are unicellular microorganisms classified within the Fungi kingdom. They are well known for their use in baking, winemaking and beer brewing fermentation, but some species of yeast are opportunistic pathogens that can cause infections in humans. "Today, yeast infections are poorly understood, difficult to diagnose, and are becoming increasingly frequent and serious, affecting over 300 million people worldwide.

26 Sep 2015

Patients with advanced kidney cancer benefit from cabozantinib treatment

Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases - enzymes that function as an "on" or "off" switch in many cellular processes, including cancer.

26 Sep 2015

NIH-supported study explores effects of substance use on adolescent brain development

The National Institutes of Health today awarded 13 grants to research institutions around the country as part of a landmark study about the effects of adolescent substance use on the developing brain.

26 Sep 2015

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited.

26 Sep 2015

Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment

Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration approved the new drug application for Tresiba (insulin degludec injection), a once-daily, long-acting basal insulin. Tresiba is indicated for use alone, or in combination with oral antidiabetic medicines or bolus insulin, and is approved for glycemic control in adults with type 1 and type 2 diabetes. Tresiba provides a long duration of action beyond 42 hours.

From Novo Nordisk 26 Sep 2015

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

New guideline on the use of prescription medications for treatment of opioid addiction

Medications play an important role in managing patients with opioid use disorders, but there are not enough physicians with the knowledge and ability to use these often-complex treatments.

25 Sep 2015

Fungi research may lead to cheaper anti-cancer drugs for humans

Cheaper anti-cancer drugs for humans might ultimately stem from a new study by University of Guelph scientists into a kind of microbial "bandage" that protects yew trees from disease-causing fungi.

25 Sep 2015

DNA nanostructures provide novel applications in molecular medicine

Researchers from Aalto University have published an article in the recent Trends in Biotechnology journal. The article discusses how DNA molecules can be assembled into tailored and complex nanostructures, and further, how these structures can find uses in therapeutics and bionanotechnological applications.

25 Sep 2015

Research highlights potential new treatment strategy for degenerative diseases

St. Jude Children's Research Hospital scientists have discovered evidence of a mechanism at the heart of amyotrophic lateral sclerosis (ALS) and related degenerative diseases. The research appears in today's edition of the journal Cell and highlights a possible new treatment strategy for the devastating disorders.

25 Sep 2015

Drugs News and Research

Mylan releases generic version of Invega in the U.S.

Increasing availability of genetic tests for at-risk cancer patients

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Two-drug combination improves progression-free survival in patients with advanced melanoma

Combination of two targeted therapies increases survival in advanced melanoma

Genetic mutations predict breast cancer relapse

Investment in radiotherapy services could save lives, boost economy in developing countries

New technology benefits child suffering from severe form of epilepsy

New countries join ESMO Designated Centre of Integrated Oncology and Palliative Care

New report sets out plans to improve cure rate, quality of life for childhood cancer survivors in Europe

Creating a new paradigm for management of yeast infections

Patients with advanced kidney cancer benefit from cabozantinib treatment

NIH-supported study explores effects of substance use on adolescent brain development

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

New guideline on the use of prescription medications for treatment of opioid addiction

Fungi research may lead to cheaper anti-cancer drugs for humans

DNA nanostructures provide novel applications in molecular medicine

Research highlights potential new treatment strategy for degenerative diseases

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News